Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Aging Clinical Trials

A listing of Aging medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (46) clinical trials

Safety Tolerability Pharmacokinetics and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell Disease

Sickle cell disease (SCD) is a multisystem disorder associated with episodes of acute clinical events and progressive organ damage. Episodic pain, triggered by micro-vasoocclusion induced by sickled red blood cells, is the most common acute complication and the leading cause of hospitalization. Management strategies for SCD have evolved very slowly, ...


A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

The main objective is to investigate ocular and systemic safety and tolerability as well as disease improvement of BI 836880 after a single Intravitreal (IVT) injection and after multiple IVT injections of several doses.


Study of NaQuinate in Healthy Volunteers

This first-in-human (FIH) clinical study is a Phase 1, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, and PK of NaQuinate in healthy subjects after single ascending oral (PO) doses and multiple ascending PO doses.


A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

The main objective is to investigate ocular and systemic safety and tolerability as well as pharmacokinetics of single intravitreal administration of BI 754132.


CLN-0046: Treatment of AMD Subjects With OTX-TKI

A multi-center, dose escalation, Phase 1, safety, tolerability and efficacy study to evaluate two dose groups of the OTX-TKI implant to treat subjects with a diagnosis of primary subfoveal neovascularization secondary to AMD.


A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine. The study will last about 6 weeks, ...


Evaluating the Safety and Immunogenicity of AGS-v PLUS a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

This study will evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers. Participants will be randomly assigned to five groups. Participants in Group 1 will receive placebo on Days 1 and 22. Participants in Group 2 will receive unadjuvanted AGS-v ...


A Study to Evaluate the Pharmacokinetics Pharmacodynamics and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).


A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration

The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates. The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the pharmacodynamics and therapeutic efficacy profile of BAT5906.


ADVM-022 Gene Therapy for Wet AMD

This open-label, multicenter, dose-escalation study will evaluate 2 dose levels in 12 subjects (6 per dose) with active choroidal neovascularization (CNV) secondary to AMD. Subjects who are under active anti-VEGF treatment and have demonstrated a meaningful response to anti-VEGF therapy will be considered for participation in this study. The primary ...